Acrux Limited (ASX:ACR)

Market Cap	6.49M +5.7%
Revenue (ttm)	6.58M +46.6%
Net Income	-604.00K
EPS	-0.00
Shares Out	589.68M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	752,158
Open	0.0100
Previous Close	0.0100
Day's Range	0.0100 - 0.0110
52-Week Range	0.0090 - 0.0210
Beta	1.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of modera...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 43
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACR

Financial Performance

In fiscal year 2026, Acrux's revenue was 6.58 million, an increase of 46.64% compared to the previous year's 4.49 million. Losses were -604,000, -89.84% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error